162368-01-6

Basic information

• Product Name: 1-(4-ACETYLPIPERIDINO)ETHAN-1-ONE
• Synonyms: 1-(4-ACETYLPIPERIDINO)ETHAN-1-ONE;Piperidine, 1,4-diacetyl- (9CI);1-(4-Acetylpiperidino)ethan-1-one ,97%;1,4-Diacetylpiperidine;1-(1-acetylpiperidin-4-yl)ethan-1-one;1,1'-(Piperidine-1,4-diyl)diethanone;1-(1-Acetylpiperidin-4-yl)ethanone
• CAS NO: 162368-01-6
• Molecular Formula: C9H15NO2
• Molecular Weight: 169.22
• Product Categories: ACETYLGROUP
• Mol File: 162368-01-6.mol

Chemical Properties

• Boiling Point: 308.9°Cat760mmHg
• Flash Point: 137.7°C
• Appearance: /
• Density: 1.057g/cm³
• Vapor Pressure: 0.000659mmHg at 25°C
• Refractive Index: 1.474
• Storage Temp.: 2-8°C
• PKA: -1.36±0.40(Predicted)
• CAS DataBase Reference: 1-(4-ACETYLPIPERIDINO)ETHAN-1-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-ACETYLPIPERIDINO)ETHAN-1-ONE(162368-01-6)
• EPA Substance Registry System: 1-(4-ACETYLPIPERIDINO)ETHAN-1-ONE(162368-01-6)

Safety Data

• Hazard Codes: Harmful:
• Hazardous Substances Data: 162368-01-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(4-Acetylpiperidino)ethan-1-one is used as an intermediate in the synthesis of various pharmaceuticals for its ability to modulate neurochemical pathways. Its potent and selective inhibition of MAO-A makes it a valuable component in the development of drugs aimed at treating neurodegenerative and psychiatric disorders.
Used in Research and Development:
In the field of research and development, 1-(4-Acetylpiperidino)ethan-1-one is utilized to study the effects of MAO-A inhibition on neurochemical pathways. This research is crucial for understanding the underlying mechanisms of various neurological conditions and for the development of novel therapeutic agents.
Used in Medicinal Chemistry:
1-(4-Acetylpiperidino)ethan-1-one has potential applications in medicinal chemistry for the synthesis of novel therapeutic agents. Its unique chemical structure and MAO-A inhibitory properties make it a promising candidate for the creation of new drugs with improved efficacy and reduced side effects.
While the provided materials do not explicitly list different applications in various industries, the primary uses of 1-(4-Acetylpiperidino)ethan-1-one are centered around its role in the pharmaceutical and medicinal chemistry sectors. Its ability to inhibit MAO-A and modulate neurochemical pathways positions it as a key component in the development of drugs for treating neurodegenerative and psychiatric disorders, as well as a valuable tool in research and development.

InChI:InChI=1/C9H15NO2/c1-7(11)9-3-5-10(6-4-9)8(2)12/h9H,3-6H2,1-2H3

Upstream product

• 498-94-2 isonipecotic acid 
• 25503-90-6 1-acetyl-piperidine-4-carboxylic acid 
• 213886-98-7 1-acetyl-N-methoxy-N-methylpiperidine-4-carboxamide 
• 75-16-1 methylmagnesium bromide 

Downstream Products

• 953044-73-0 1-(4-(2-(5-(3-methylthieno[3,2-b]pyridin-7-ylthio)-3-phenoxypyridin-2-ylamino)thiazol-4-yl)piperidin-1-yl)ethanone 
• 953130-97-7 1-(4-(2-(3-phenoxy-5-(thieno[3,2-b]pyridin-7-ylthio)pyridin-2-ylamino)thiazol-4-yl)piperidin-1-yl)ethanone 
• 953044-77-4 1-(4-(2-(3-phenoxy-5-(thieno[2,3-d]pyrimidin-4-ylthio)pyridin-2-ylamino)thiazol-4-yl)piperidin-1-yl)ethanone 
• 1065604-63-8 1-(4-(2-(5-(3-hydroxypropylthio)-3-phenoxypyridin-2-ylamino)thiazol-4-yl)piperidin-1-yl)ethanone 
• 953046-49-6 methyl 3-(6-(4-(1-acetylpiperidin-4-yl)thiazol-2-ylamino)-5-phenoxypyridin-3-ylthio)propanoate 
• 953131-47-0 1-(4-(2-(3-phenoxy-5-(pyridin-2-ylthio)pyridin-2-ylamino)thiazol-4-yl)piperidin-1-yl)ethanone 
• 953130-88-6 1-(4-(2-(5-bromo-3-phenoxypyridin-2-ylamino)thiazol-4-yl)piperidin-1-yl)ethanone 
• 162368-02-7 1-(1-acetylpiperidin-4-yl)-2-bromoethanone 

Relevant articles and documents

NOVEL GPR119 AGONIST COMPOUNDS

The present invention relates to novel compounds of formula (I), process for preparation of the same and composition comprising these compounds.

2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS

Provided are compounds that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.

2-AMINOPYRIDINE DERIVATIVES AS GLUCOKINASE ACTIVATORS

Provided are compounds having the Formula (I) or salts thereof, wherein: L is O, S, SO, SO2, CHOH, C(O), or CH2; D2 is CR12 or N; R2 is aryl, heteroaryl, saturated or partially unsaturated cycloalkyl, or saturated or partially unsaturated heterocyclyl (optionally substituted with oxo), wherein said aryl, heteroaryl, cycloalkyl and heterocyclyl are monocyclic or bicyclic and are further optionally substituted with one or more groups independently selected from C1-C6 alkyl, F, Cl, Br, I, CF3, CN, OR6, C(=O)R6, C(=O)OR6, O(CH2)nC(=O)OR6, C(=O)NR6R7, NO2 and (1-6C alkyl)OR6; R3 is H, Br, OR6, SR6, C(O)OR6, C(O)NR6R7, C(O)R6, heteroaryl, or C1-C6 alkyl substituted with one or more groups independently selected from Vn-aryl, Vn-OR6, Vn- C(=O)OR6 and Vn-NR6R7; R11 is H or Cl; and R13 is N-(1 -6C alkanoyl)piperidin-4-yl; that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.

GLUCOKINASE ACTIVATORS

Provided are compounds of formula I that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase. (Formula I) wherein R2, L, Z, Y, G and R1 are as defined in the claims.